High sdLDL-C and Lipoprotein(A) Levels Correlated to Coronary Arteriostenosis in Takayasu Arteritis
By LabMedica International staff writers Posted on 11 Nov 2021 |

Image: The Beckman AU5400 automatic biochemical analyzer (Photo courtesy of Beckman Coulter)
Takayasu arteritis (TA) is a rare vasculitis that mainly involves the aorta and its major branches. TA is mainly seen in young women aged 20–40 years and is most often encountered in Japan, Southeast Asia, India, and Mexico. Due to nonspecific clinical features, TA patients with coronary arteriostenosis might be misdiagnosed or inappropriately treated.
Dyslipidemia plays a role in the pathogenesis of TA, and the lipid profiles in TA patients are pro-atherogenic. Small dense low-density lipoprotein cholesterol (sdLDL-C) is small and highly dense relative to other LDL-C particles and thought to be more atherogenic than the large buoyant LDL (lb-LDL) due to greater penetration into the arterial wall, a prolonged plasma half-life, lower hepatic LDL receptor affinity, and higher susceptibility to oxidation.
Clinical Laboratorians at the Capital Medical University (Beijing, China) retrospectively studied 190 TA patients and 154 healthy subjects. TA patients were divided into three categories based on the degree of coronary stenosis: Group I, stenosis >50%; Group II, stenosis 1%–50%; and Group III, stenosis 0%. Independent risk factors for coronary arteriostenosis in TA were identified by logistic regression, followed by receiver operating characteristic curve analysis to determine the specificity and sensitivity of risk factors and Youden's Index score calculation to determine the cutoff points.
The team obtained early in the morning, venous blood samples were from fasting TA patients and healthy controls. The team previously compared methods for measuring sdLDL-C, and a Beckman AU5400 automatic biochemical analyzer (Beckman Coulter, Brea, CA, USA) and was used in the present study to measure novel and traditional lipid parameters and biochemical indicators, including the sdLDL-C, Lp(a), total cholesterol (TC), LDL-C, HDL-C, and triglyceride (TG) concentrations within 5–6 hours after sample collection. The Sysmex XE-2100 (Sysmex Corporation, Kobe, Japan) was used to determine complete blood counts.
The investigators reported Takayasu arteritis patients had significantly higher serum levels of sdLDL-C and Lp(a) than healthy controls. The total cholesterol, triglyceride, LDL-C, sdLDL-C, and Lp(a) levels and the sdLDL-C/LDL-C ratio in Group I were significantly higher than those in Groups II and III. An elevated serum sdLDL-C level elevated the risk of coronary arteriostenosis by 5-fold (cutoff value, 0.605 mmol/L). An increased serum Lp(a) level increased the risk of coronary arteriostenosis by 3.9-fold (cutoff value, 0.045 g/L). An elevated sdLDL-C/LDL-C ratio increased the risk of coronary arteriostenosis by 2.1-fold (cutoff value, 0.258).
The authors concluded that TA patients had higher serum sdLDL-C and Lp(a) concentrations than healthy individuals and TA patients with coronary arteriostenosis had significantly higher serum levels of sdLDL-C and Lp(a) than those without coronary arteriostenosis. Additionally, serum sdLDL-C and Lp(a) concentrations and the sdLDL-C/LDL-C ratio might be used as diagnostic factors for coronary arteriostenosis in TA patients. The study was published on October 28, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Capital Medical University
Beckman Coulter
Sysmex Corporation
Dyslipidemia plays a role in the pathogenesis of TA, and the lipid profiles in TA patients are pro-atherogenic. Small dense low-density lipoprotein cholesterol (sdLDL-C) is small and highly dense relative to other LDL-C particles and thought to be more atherogenic than the large buoyant LDL (lb-LDL) due to greater penetration into the arterial wall, a prolonged plasma half-life, lower hepatic LDL receptor affinity, and higher susceptibility to oxidation.
Clinical Laboratorians at the Capital Medical University (Beijing, China) retrospectively studied 190 TA patients and 154 healthy subjects. TA patients were divided into three categories based on the degree of coronary stenosis: Group I, stenosis >50%; Group II, stenosis 1%–50%; and Group III, stenosis 0%. Independent risk factors for coronary arteriostenosis in TA were identified by logistic regression, followed by receiver operating characteristic curve analysis to determine the specificity and sensitivity of risk factors and Youden's Index score calculation to determine the cutoff points.
The team obtained early in the morning, venous blood samples were from fasting TA patients and healthy controls. The team previously compared methods for measuring sdLDL-C, and a Beckman AU5400 automatic biochemical analyzer (Beckman Coulter, Brea, CA, USA) and was used in the present study to measure novel and traditional lipid parameters and biochemical indicators, including the sdLDL-C, Lp(a), total cholesterol (TC), LDL-C, HDL-C, and triglyceride (TG) concentrations within 5–6 hours after sample collection. The Sysmex XE-2100 (Sysmex Corporation, Kobe, Japan) was used to determine complete blood counts.
The investigators reported Takayasu arteritis patients had significantly higher serum levels of sdLDL-C and Lp(a) than healthy controls. The total cholesterol, triglyceride, LDL-C, sdLDL-C, and Lp(a) levels and the sdLDL-C/LDL-C ratio in Group I were significantly higher than those in Groups II and III. An elevated serum sdLDL-C level elevated the risk of coronary arteriostenosis by 5-fold (cutoff value, 0.605 mmol/L). An increased serum Lp(a) level increased the risk of coronary arteriostenosis by 3.9-fold (cutoff value, 0.045 g/L). An elevated sdLDL-C/LDL-C ratio increased the risk of coronary arteriostenosis by 2.1-fold (cutoff value, 0.258).
The authors concluded that TA patients had higher serum sdLDL-C and Lp(a) concentrations than healthy individuals and TA patients with coronary arteriostenosis had significantly higher serum levels of sdLDL-C and Lp(a) than those without coronary arteriostenosis. Additionally, serum sdLDL-C and Lp(a) concentrations and the sdLDL-C/LDL-C ratio might be used as diagnostic factors for coronary arteriostenosis in TA patients. The study was published on October 28, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Capital Medical University
Beckman Coulter
Sysmex Corporation
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more